Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vernalis and Servier have attained a research milestone in their oncology drug discovery collaboration which was initiated in May 2007.
Subscribe to our email newsletter
The collaboration was made to develop two oncology targets involved in protein-protein interactions using Vernalis’ proprietary drug discovery platform.
The research milestone allows the collaboration to be expanded and extended for a third oncology target.
Vernalis will receive a payment of € 0.5m from Servier in recognition of reaching this stage in the programme.
Servier Research and Development president Emmanuel Canet said they are satisfied with this collaboration showing the added value of integrated structural biology and reaching a milestone on a oncology target.
"This is a step further in our aim to finalise the discovery of compounds with potential use in therapeutic indications with high unmet medical need," Canet said.